Homeland Preparedness News ∙ 10/22/2020 ∙ CTSA Program
The Biomedical Advanced Research and Development Authority (BARDA) has enlisted its clinical studies network’s services to assist with a COVID-19 clinical trial. Officials said Technical Resources International, Inc., a BARDA subsidiary, would support the clinical trial in conjunction with the NIH-led Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative (ACTIV-1).
The work scope involves evaluating three immune modulator drugs in treating hospitalized adults with COVID-19. NCATS is slated to coordinate and oversee the clinical trial with funding and other support from BARDA.